Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
70.18 USD | -3.98% | +0.83% | -11.68% |
Financials (USD)
Sales 2024 * | 379M | Sales 2025 * | 686M | Capitalization | 3.46B |
---|---|---|---|---|---|
Net income 2024 * | -178M | Net income 2025 * | 60M | EV / Sales 2024 * | 8.92 x |
Net cash position 2024 * | 77.32M | Net cash position 2025 * | 136M | EV / Sales 2025 * | 4.85 x |
P/E ratio 2024 * |
-19.6
x | P/E ratio 2025 * |
66
x | Employees | 545 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.69% |
Latest transcript on Axsome Therapeutics, Inc.
1 day | +2.78% | ||
1 week | +6.21% | ||
Current month | -8.42% | ||
1 month | -9.40% | ||
3 months | -18.36% | ||
6 months | +17.85% | ||
Current year | -8.18% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 55 | 12-01-11 | |
Nick Pizzie
DFI | Director of Finance/CFO | 49 | 18-05-15 |
Mark Jacobson
COO | Chief Operating Officer | 40 | 14-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Saad
BRD | Director/Board Member | 54 | 14-11-30 |
Susan Mahony
BRD | Director/Board Member | 60 | 23-10-10 |
Roger Jeffs
BRD | Director/Board Member | 62 | 14-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.26% | 0 M€ | 0.00% | - | |
0.14% | 237 M€ | +1.33% | - | |
0.14% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 70.28 | -3.83% | 307 166 |
24-04-23 | 73.08 | +2.78% | 703,139 |
24-04-22 | 71.1 | +4.71% | 498,859 |
24-04-19 | 67.9 | +3.32% | 930,832 |
24-04-18 | 65.72 | -5.72% | 834,897 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.18% | 3.46B | |
-2.86% | 87.37B | |
+4.08% | 41.01B | |
-25.35% | 28.08B | |
+54.12% | 24.72B | |
-4.52% | 17.47B | |
-42.09% | 11.69B | |
-17.77% | 11.6B | |
-12.10% | 11.56B | |
+1.50% | 8.44B |
- Stock Market
- Equities
- AXSM Stock